Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities.

Coppé JP, Mori M, Pan B, Yau C, Wolf DM, Ruiz-Saenz A, Brunen D, Prahallad A, Cornelissen-Steijger P, Kemper K, Posch C, Wang C, Dreyer CA, Krijgsman O, Lee PRE, Chen Z, Peeper DS, Moasser MM, Bernards R, van 't Veer LJ.

Nat Cell Biol. 2019 Jun;21(6):778-790. doi: 10.1038/s41556-019-0328-z. Epub 2019 Jun 3.

PMID:
31160710
2.

An ATG16L1-dependent pathway promotes plasma membrane repair and limits Listeria monocytogenes cell-to-cell spread.

Tan JMJ, Mellouk N, Osborne SE, Ammendolia DA, Dyer DN, Li R, Brunen D, van Rijn JM, Huang J, Czuczman MA, Cemma MA, Won AM, Yip CM, Xavier RJ, MacDuff DA, Reggiori F, Debnath J, Yoshimori T, Kim PK, Fairn GD, Coyaud E, Raught B, Muise AM, Higgins DE, Brumell JH.

Nat Microbiol. 2018 Dec;3(12):1472-1485. doi: 10.1038/s41564-018-0293-5. Epub 2018 Nov 26.

PMID:
30478389
3.

An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.

Wang L, Leite de Oliveira R, Huijberts S, Bosdriesz E, Pencheva N, Brunen D, Bosma A, Song JY, Zevenhoven J, Los-de Vries GT, Horlings H, Nuijen B, Beijnen JH, Schellens JHM, Bernards R.

Cell. 2018 May 31;173(6):1413-1425.e14. doi: 10.1016/j.cell.2018.04.012. Epub 2018 May 10.

4.

PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma.

Brunen D, de Vries RC, Lieftink C, Beijersbergen RL, Bernards R.

Mol Cancer Ther. 2018 Apr;17(4):849-857. doi: 10.1158/1535-7163.MCT-17-0868. Epub 2018 Feb 13.

5.

Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data.

Sinha S, Thomas D, Chan S, Gao Y, Brunen D, Torabi D, Reinisch A, Hernandez D, Chan A, Rankin EB, Bernards R, Majeti R, Dill DL.

Nat Commun. 2017 May 31;8:15580. doi: 10.1038/ncomms15580.

6.

Drug therapy: Exploiting synthetic lethality to improve cancer therapy.

Brunen D, Bernards R.

Nat Rev Clin Oncol. 2017 Jun;14(6):331-332. doi: 10.1038/nrclinonc.2017.46. Epub 2017 Mar 29. No abstract available.

PMID:
28352131
7.

Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling.

Brunen D, García-Barchino MJ, Malani D, Jagalur Basheer N, Lieftink C, Beijersbergen RL, Murumägi A, Porkka K, Wolf M, Zwaan CM, Fornerod M, Kallioniemi O, Martínez-Climent JÁ, Bernards R.

Oncotarget. 2016 Jun 21;7(25):37407-37419. doi: 10.18632/oncotarget.9822.

8.

FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.

Koole K, Brunen D, van Kempen PM, Noorlag R, de Bree R, Lieftink C, van Es RJ, Bernards R, Willems SM.

Clin Cancer Res. 2016 Aug 1;22(15):3884-93. doi: 10.1158/1078-0432.CCR-15-1874. Epub 2016 Mar 2.

9.

TGF-β: an emerging player in drug resistance.

Brunen D, Willems SM, Kellner U, Midgley R, Simon I, Bernards R.

Cell Cycle. 2013 Sep 15;12(18):2960-8. doi: 10.4161/cc.26034. Epub 2013 Aug 12.

10.

Rapid temporal control of Foxp3 protein degradation by sirtuin-1.

van Loosdregt J, Brunen D, Fleskens V, Pals CE, Lam EW, Coffer PJ.

PLoS One. 2011 Apr 20;6(4):e19047. doi: 10.1371/journal.pone.0019047.

11.

High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates.

Verheyen J, Verhofstede C, Knops E, Vandekerckhove L, Fun A, Brunen D, Dauwe K, Wensing AM, Pfister H, Kaiser R, Nijhuis M.

AIDS. 2010 Mar 13;24(5):669-73. doi: 10.1097/QAD.0b013e32833160fa.

PMID:
19926962

Supplemental Content

Loading ...
Support Center